Diffuse large B-cell lymphoma – an aggressive form of non ... which is bound to a cytotoxic agent by a linker that is stable in the circulation but degrades when inside the target cell.

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal ...

B-cell therapy (also called B-cell depletion therapy) is a treatment for people with multiple sclerosis (MS). It targets certain cells -- called B cells -- that can damage nerve fibers in your ...

SAVANNAH, Georgia — Inebilizumab, a first-in-class anti-CD19 B-cell depleting agent, demonstrated both safety and superior efficacy compared with placebo in patients with seropositive ...

This article was supported by Regione Veneto, Ricerca Sanitaria Finalizzata; Fondazione G Berlucchi per la Ricerca sul Cancro; Fondazione Cassa di Risparmio di Verona, Vicenza, Belluno e Ancona ...

Linker design should balance stability and release kinetics, while payloads should be potent and have minimal toxic side effects. Conjugation methods must ensure uniformity and stability of the ADC.

B cells are a type of white blood cell. They make antibodies -- proteins that fight viruses and bacteria. B cells normally can’t cross from your blood into your brain or spinal cord. If you have ...

Vincerx’s pipeline includes a clinical-stage small molecule drug program in diffuse large B cell lymphoma and other ... been limited by current payload-linker chemistries. In the second half ...

in participants with selected CD19+ and CD20+ relapsed/refractory B-cell NHL. The phase 1, open label clinical study is designed to enroll up to 10 participants and is being conducted in ...

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug ...

Celltrion Inc. posted preclinical study results of two new antibody-drug conjugate (ADC) candidates – CT-P70 and CT-P71 – at the World ADC 2024 conference in San Diego Nov. 6, with plans to move the ...

We are pleased that the European Commission approved Ordspono or odronextamab, or CD20xCD3 bispecific for relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, marking the ...